Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202110055 A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202201004 A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure. Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202201024 An open-label study to evaluate the effectiveness and safety of EZYPRO® in atrial fibrillation detection in nearly embolic stroke of undetermined source (ESUS) patient Atrial fibrillation SHH Neurology

Lung Chan

 02-6620-2589
N202201030 A randomized, evaluator-blinded, controlled study to evaluate the safety and clinical performance of OIF/β-TCP in patients with open tibial fractures in need of bone grafting. Tibial fracture SHH Orthopedics

Chih-Hwa Chen

 02-6620-2589
N202202008 A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC 9) Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202203001 A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) Focal segmental glomerulosclerosis (FSGS) SHH Nephrology

Mai-Szu Wu

 02-6620-2589
N202203156 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy Nephropathy SHH Nephrology

Yung-Ho Hsu

 02-6620-2589
N202204040 A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination with First-Line Erlotinib in Patients with EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202205015 A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS) Ischemic stroke SHH Neurology

Lung Chan

 02-6620-2589
N202206023 A PHASE 3 RANDOMIZED CONTROLLED STUDY OF RENAL AUTOLOGOUS CELL THERAPY (REACT) IN SUBJECTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (REGEN-006) Diabetes and Chronic Kidney Disease SHH Nephrology

Mai-Szu Wu

 02-6620-2589
1 2 3 4 5 6 / 6

TOP